SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novavax NVAX
NVAX 7.910-5.8%Nov 3 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Glenn Petersen who wrote (55)8/10/2009 1:17:07 PM
From: Rock_nj   of 166
 
Cadila Pharma to produce swine flu vaccine (with Novavax)
TNN 10 August 2009, 06:38pm IST

NEW DELHI: Ahmedabad-based Cadila pharma to become the first firm to manufacture vaccine for H1N1 in India. US-based biotechnology firm Novavax, in which Cadila has equity stake, has developed vaccine for the treatment of H1N1 virus. Two shots of vaccine within 3-week period will immunize person against flu.

Cadila says clinical trials on animals have been completed and tests on humans will begin in Ahmedabad shortly.

Cadila is approaching government for fast track clearance and hopes to manufacture vaccine by 2009 end. Initialy, it plans capacity of 2 million vaccines per month.

timesofindia.indiatimes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext